Targeting CD276 for T cell-based immunotherapy of breast cancer

Abstract Background Breast cancer (BC) is the most common malignancy in women. Immunotherapy has revolutionized treatment options in many malignancies, and the introduction of immune checkpoint inhibition yielded beneficial results also in BC. However, many BC patients are ineligible for this T cell...

Full description

Bibliographic Details
Published in:Journal of Translational Medicine
Main Authors: Ilona Hagelstein, Laura Wessling, Alexander Rochwarger, Latifa Zekri, Boris Klimovich, Christian M. Tegeler, Gundram Jung, Christian M. Schürch, Helmut R. Salih, Martina S. Lutz
Format: Article
Language:English
Published: BMC 2024-10-01
Subjects:
Breast cancer
CD276
B7-H3
CD3
Bispecific antibody
T cell
Online Access:https://doi.org/10.1186/s12967-024-05689-4

Internet

https://doi.org/10.1186/s12967-024-05689-4

Similar Items